DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 020741/S-041
NDA 020741/S-042

SUPPLEMENT APPROVAL

Novo-Nordisk Inc.
Attention: Patricia Robson
Senior Manager, Regulatory Affairs
P O Box 846
Plainsboro, NJ 08536

Dear Ms. Robson:

Please refer to your Supplemental New Drug Applications (sNDAs) dated June 22, 2012, received June 22, 2012 (S-041), and dated March 23, 2015, received March 23, 2015 (S-042), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Prandin (repaglinide) tablets, 0.5, 1.0, and 2.0 mg.

These "Prior Approval supplemental new drug applications provide for the following:

- S-041 - the conversion of the prescribing information to Physician Labeling Rule (PLR) format

- S-042 - addition of drug-drug interaction information regarding concomitant use of repaglinide and clopidogrel to the clinical pharmacology section of the prescribing information.

APPROVAL & LABELING

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text and with the minor editorial revisions listed below:

- Revision date updated to reflect the date of approval

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the prescribing information), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your supplemental application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Abolade (Bola) Adeolu, Regulatory Project Manager, at (301) 796-4264.

Sincerely,

{See appended electronic signature page}

Jean-Marc Guettier, MD
Director
Division of Metabolism & Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE:
Prescribing Information

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JEAN-MARC P GUETTIER
02/08/2017